Sweden · Delayed Price · Currency is SEK BioArctic AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw robust royalty growth and strong cash reserves, driven by Leqembi's global expansion and pipeline progress. Regulatory and reimbursement hurdles persist in Europe, but U.S. and Asian markets are fueling blockbuster momentum.
Fiscal Year 2025
-
2025 was a record year with SEK 1.2 billion in revenue, driven by Leqembi's global sales surpassing $500 million and strong pipeline progress. The company maintains a robust cash position, proposes a SEK 2 per share dividend, and expects continued growth and R&D investment in 2026.
-
LEQEMBI demand and global approvals continue to rise, with strong financials driven by royalties, milestones, and new partnerships. U.S. and Japan sales are growing, while China is expected to recover after Q4 inventory effects. The pipeline expands with new projects and collaborations.
-
Profitable growth continues with record Q2 revenues, driven by Leqembi sales and a major Novartis partnership. Leqembi launches expand in Europe, and exidavnemab advances in clinical trials. Strong cash reserves and recurring royalties support a positive outlook.
-
Entering a growth era, the company is expanding its R&D pipeline and business development, with Leqembi driving recurring royalties and profitability expected in 2025. The BrainTransporter platform and selective antibody programs position the firm as a leader in precision neurology, with robust partnerships and a strong financial outlook.
-
Q1 saw record revenues and profit, driven by major upfront and milestone payments, strong Leqembi royalties, and expanding global market access. The company expects continued profitability, increased R&D and commercial investment, and further growth from partnerships and new indications.
Fiscal Year 2024
-
Major license deal with BMS and surging Leqembi sales drove strong Q4 results, with recurring royalties and a robust cash position setting up expected profitability in 2025. Pipeline progress includes exidavnemab phase IIa and expanding BrainTransporter partnerships.
-
Pipeline and brain transporter technology are advancing, with Leqembi royalties up 64% sequentially and strong sales growth in the U.S., Japan, and China. Financials remain robust with SEK 800 million in cash, supporting increased R&D and future profitability as royalties grow.
-
Leqembi sales and royalties surged in Q2, driven by strong launches in the U.S., Japan, and China, with global approvals now covering over 80% of the expected market. Financials showed robust royalty growth and a solid cash position, while the pipeline advanced with new agreements and upcoming clinical trials.